Abstract
The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent or delay PTDM development, while early detection facilitates prompt management and may prevent acute and chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia and other indices, in addition to those solely based on clinical parameters. We also examine the available methods for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose (FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant. FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may lead to improvements in patient survival, quality of life and health care costs in future.
Keywords: Post transplant diabetes, PTDM, prediction, diagnosis.
Current Diabetes Reviews
Title:Prediction and Diagnosis of Post Transplant Diabetes
Volume: 11 Issue: 3
Author(s): Christopher J. Yates and Solomon J. Cohney
Affiliation:
Keywords: Post transplant diabetes, PTDM, prediction, diagnosis.
Abstract: The identification of at-risk individuals prior to transplantation may enable implementation of measures to prevent or delay PTDM development, while early detection facilitates prompt management and may prevent acute and chronic complications. Thus, in this review, we examine proposed tools for the prediction of PTDM for use prior to and following solid organ transplantation. This includes PTDM prediction models based on biochemical assessments of glycaemia and other indices, in addition to those solely based on clinical parameters. We also examine the available methods for diagnosis of PTDM early and late post-transplant, including the advantages and limitations of fasting plasma glucose (FPG), OGTT, random plasma glucose and HbA1c assessment. Key findings are that OGTT should remain the gold standard diagnostic method for PTDM, however, there is emerging data to support a role for HbA1c beyond 3 months posttransplant. FPG has low sensitivity during the first year post-transplant. Improved prediction and diagnosis of PTDM may lead to improvements in patient survival, quality of life and health care costs in future.
Export Options
About this article
Cite this article as:
Yates J. Christopher and Cohney J. Solomon, Prediction and Diagnosis of Post Transplant Diabetes, Current Diabetes Reviews 2015; 11 (3) . https://dx.doi.org/10.2174/1573399811999150316105553
DOI https://dx.doi.org/10.2174/1573399811999150316105553 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Genes of Human Longevity: An Endless Quest?
Current Vascular Pharmacology Multiple Protective Functions of Sigma1 Receptor
Current Protein & Peptide Science The Possible Hypoglycemic Mechanisms of Echinochrome
Current Diabetes Reviews Role of Neurotrophins in Spinal Plasticity and Locomotion
Current Pharmaceutical Design Water and Ion Channels: Crucial in the Initiation and Progression of Apoptosis in Central Nervous System?
Current Neuropharmacology Nanomedicine
Current Nanoscience Current Metabolomic Methodologies & their Application to Thermal Stress
Current Metabolomics Unfolded Protein Response in Chronic Obstructive Pulmonary Disease: Smoking, Aging and Disease: A SAD Trifecta
Current Molecular Medicine Are Gap Junction Channels a Therapeutic Target and if so What Properties are Best Exploited?
Current Drug Targets Manipulating Kynurenic Acid Levels in the Brain – On the Edge Between Neuroprotection and Cognitive Dysfunction
Current Topics in Medicinal Chemistry Pharmacologic Targeting of Endothelial Progenitor Cells
Cardiovascular & Hematological Disorders-Drug Targets Gene Therapy for Peripheral Nervous System Diseases
Current Gene Therapy Complex and Differential Glial Responses in Alzheimer´s Disease and Ageing
Current Alzheimer Research Oxidative Stress Protection by Novel Telomerase Activators in Mesenchymal Stem Cells Derived from Healthy and Diseased Individuals
Current Molecular Medicine Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy Neuroprotective Efficacy of the Peroxisome Proliferator-Activated Receptor-γ Ligand in Chronic Cerebral Hypoperfusion
Current Neurovascular Research Development of Enzyme-Linked Immunosorbent Assay System for PEDF and its Clinical Utility
Current Molecular Medicine Nox Inhibitors & Therapies: Rational Design of Peptidic and Small Molecule Inhibitors
Current Pharmaceutical Design Pharmacodynamics of Memantine: An Update
Current Neuropharmacology